Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: Impact on oral bioavailability, absorption, and metabolic disposition in rats

References

• al-Balla SR, el-Sayed YM, al-Meshal MA, Gouda MW. The effects of cholestyramine and colestipol on the absorption of diclofenac in man. International Journal of Clinical Pharmacology and Therapeutics 1994; 32: 441–445
   Google Scholar
• al-Meshal MA, el-Sayed YM, al-Balla SR, Gouda MW. The effect of colestipol and cholestyramine on ibuprofen bioavailability in man. Biopharmaceutics and Drug Disposition 1994; 15: 463–471
   Google Scholar
• Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. British Journal of Clinical Pharmacology 1999; 48: 424–432
   PubMed Web of Science ®Google Scholar
• Berger K, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD. Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996; 137: 4189–4195
   PubMed Web of Science ®Google Scholar
• Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD. The fate of a thiazolidinediones antidiabetic in rat and dog. Xenobiotica 1996; 26: 627–636
   Web of Science ®Google Scholar
• Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID) in man. European Journal of Clinical Pharmacology 1995; 48: 269–272
   PubMed Web of Science ®Google Scholar
• Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H. Drug Metabolism and Disposition 2000; 28: 772–780
   PubMed Web of Science ®Google Scholar
• Dollery C. Cholestyramine. Therapeutic Drugs. Churchill Livingstone, Edinburgh 1991; 1: C225–C228
   Google Scholar
• el-Sayed YM, al-Meshal MA, al-Angary AA, Lufti KM, Gouda MW. The effect of colestipol and cholestyramine on systemic clearance of intravenous ibuprofen in rabbits. Journal of Pharmacy and Pharmacology 1994; 46: 73–75
   Google Scholar
• Ferry DG, Gazeley LR, Busby WJ, Beasley DM, Edwards IR, Campbell AJ. Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. European Journal of Clinical Pharmacology 1990; 39: 599–601
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics2nd. Dekker, New York, NY 1982
   Google Scholar
• GlaxoSmithKline. AVANDIA® (rosiglitazone maleate) tablets. 2005, Prescribing information (available at: http://www.fda.gov/medwaTCH/SAFETY/2005/Jan-PI/Avandia_PI.pdf)
   Google Scholar
• Guentert TW, Defoin R, Mosberg H. The influence of cholestyramine on the elimination of tenoxicam and piroxicam. European Journal of Clinical Pharmacology 1988; 34: 283–289
   PubMed Web of Science ®Google Scholar
• Hibbard DM, Peters JR, Hunninghake DB. Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. British Journal of Clinical Pharmacology 1984; 18: 337–342
   Google Scholar
• Hoppner K, Lampi B. Bioavailability of folate following ingestion of cholestyramine in the rat. International Journal for Vitamin and Nutrition Research 1991; 61: 130–134
   Google Scholar
• Hunninghake DB, Hibbard DM. Influence of the time intervals for cholestyramine dosing on the absorption of hydrochlorthiazide. Clinical and Pharmacology Therapy 1986; 39: 329–334
   Google Scholar
• Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. International Journal of Clinical Pharmacology Therapy and Toxicology 1982; 20: 151–154
   Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA. An antidiabetic thiazolidinediones is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry 1995; 270: 12953–12956
   PubMed Web of Science ®Google Scholar
• Malloy MJ, Ravis WR, Pennell AT, Diskin CJ. Effect of cholestyramine resin on single dose valprovate pharmacokinetics. International Journal of Clinical Pharmacology and Therapeutics 1996; 34: 208–211
   PubMed Web of Science ®Google Scholar
• Malloy MJ, Ravis WR, Pennell AT, Hagan DR, Betagari S, Doshi DH. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics. International Journal of Clinical Pharmacology and Therapeutics 1994; 32: 286–289
   Google Scholar
• Mamidi RN, Chaluvadi MR, Benjamin B, Ramesh M, Katneni K, Babu AP, Bhanduri J, Rao NM, Rajagopalan R. HPLC method for the determination of Rosiglitazone in human plasma and its application in a clinical Pharmacokinetics study. Arzneimittelforschung 2002; 52: 560–564
   PubMed Web of Science ®Google Scholar
• Matthews DR, Bakst A, Weston WM, Henyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetolgia 1999; 42(Suppl. 1)A228
   Google Scholar
• Meinertz T, Gilfrich HJ, Groth U, Jonen HG, Jahnchen E. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clinical Pharmacology and Therapeutics 1977; 21: 731–735
   PubMed Web of Science ®Google Scholar
• Muck W, Ritter W, Frey R, Wetzelsberger N, Lucker PW, Kuhlmann J. Influence of cholestyramine on the pharmacokinetics of cerivastatin. International Journal of Clinical Pharmacology and Therapeutics 1997; 35: 250–254
   Google Scholar
• Nakai A, Nishikata M, Matusyama K, Ichikawa M. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Biological and Pharmaceutical Bulletin 1996; 19: 1231–1233
   Google Scholar
• Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increase the plasma concentrations of rosiglitazone. Diabetolgia 2003; 46: 1319–1323
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P4502C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics 2004; 76: 239–249
   PubMed Web of Science ®Google Scholar
• Patel J, Miller E, Patwardhan R. Rosiglitazone 011 Study Group. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes 1998; 47(Suppl. 1)17
   Google Scholar
• Phillips WA, Ratchford JM, Schultz JR. Effect of colestipol hydrochloride on drug absorption in the rat II. Journal of Pharmaceutical Sciences 1976; 65: 1285–1291
   Google Scholar
• Rao MN, Mullangi R, Katneni K, Ravikanth B, Babu AP, Rani UP, Naidu MU, Srinivas NR, Rajagopalan R. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. Journal of Clinical Pharmacology 2002; 42: 670–675
   Google Scholar
• Rowland M, Tozer TN. Clinical pharmacokinetics concepts and applications3rd. Williams & Wilkins, Baltimore, MD 1995; 478–484
   Google Scholar
• Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metabolism and Disposition 2002; 30: 1352–1356
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is potent inhibitor of human cytochrome P4502C9. Drug Metabolism and Disposition 2001; 29: 1359–1361
   PubMed Web of Science ®Google Scholar
• West RJ, Lloyd JK. The effect of cholestyramine on the intestinal absorption. Gut 1975; 16: 93–98
   PubMed Web of Science ®Google Scholar
• Wilson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehman JM. Structure–activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Journal of Medicinal Chemistry 1996; 39: 665–668
   PubMed Web of Science ®Google Scholar
• Young MA, Lettis S, Eastmond R. Concomitant administration of cholestyramine influences the absorption of troglitazone. British Journal of Clinical Pharmacology 1998a; 45: 37–40
   PubMed Web of Science ®Google Scholar
• Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BR-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. Journal of Pharmacology and Experimental Therapeutics 1998b; 284: 751–759
   PubMed Web of Science ®Google Scholar